Oncology Ventures Announces Oversubscribed $62 Million Fund II to Accelerate the Future of Cancer Care

肿瘤学风险投资公司宣布超额认购6200万美元的基金II，以加速癌症治疗的未来。

AUSTIN, Texas, April 22, 2026-- Oncology Ventures announced the close of its oversubscribed $62 million Fund II, nearly double the size of its $32 million Fund I and surpassing its $50 million target. The Fund is anchored by Texas Oncology, the largest physician-led oncology-focused practice in America, alongside renewed backing from the most influential institutions in cancer care..

德克萨斯州奥斯汀，2026年4月22日——肿瘤学风险投资公司宣布其超额认购的6200万美元基金II完成募集，该基金规模几乎是其3200万美元基金I的两倍，并超过了5000万美元的目标。该基金由美国最大的医生主导的肿瘤学实践机构德州肿瘤学（Texas Oncology）领投，同时再次获得了癌症治疗领域最具影响力机构的支持。

'1,700 people die of cancer every day in the U.S.,' said Ben Freeberg, Founder and Managing Partner. 'Research shows that more than 1,000 of those deaths could be prevented with earlier detection, guideline-based treatment, and better navigation. Making cancer care more accessible, affordable and easier for patients to understand isn’t something we can wait for.'.

“美国每天有 1,700 人死于癌症，”创始人兼管理合伙人本·弗里伯格表示。“研究表明，其中 1,000 多例死亡可以通过早期检测、基于指南的治疗和更好的引导来预防。让癌症护理更易获取、更实惠且更易于患者理解，这是我们无法等待的事情。”

Freeberg knows this firsthand. After surviving a Stage 3a cancer diagnosis, marked by a year of misdiagnosis, neutropenia, 40 daily medications, and multiple surgeries, he launched Oncology Ventures to fix the system from the inside. He brings what he calls a 'triple perspective advantage': the lens of an investor (former VP at Optum Ventures), a cancer start-up operator (Thyme Care, now valued at $1B), and a patient..

弗里伯格对此深有体会。在经历第三期癌症的误诊、中性粒细胞减少症、每天服用40种药物以及多次手术后，他创立了肿瘤学风险投资公司，试图从内部修复这一系统。他带来了所谓的“三重视角优势”：投资者的视角（前Optum Ventures副总裁）、癌症初创企业经营者（Thyme Care，目前估值10亿美元）以及患者。

Oncology Ventures invests in the picks-and-shovels of a $225 billion oncology market growing at 12% annually, and the #1 cost driver for large employers and commercial health plans.

肿瘤学投资公司在规模达2250亿美元、年增长率为12%的肿瘤学市场中，投资于“镐头和铲子”，这是大型雇主和商业健康计划的首要成本驱动因素。

Oncology Ventures' limited partner network spans institutions that collectively treat one in three cancer patients in the U.S. Fund I partners Moffitt Cancer Center, City of Hope, Atlantic Health, and Cardinal Health are back for Fund II, and are joined by Texas Oncology, Fred Hutch Cancer Center and other leading institutions..

肿瘤学风险投资公司的有限合伙人网络覆盖的机构总共治疗了美国三分之一的癌症患者。基金I的合作伙伴，包括莫菲特癌症中心、希望之城、大西洋健康和红衣主教健康，再次参与基金II，并迎来了德州肿瘤学、弗雷德·哈奇癌症中心及其他领先机构的加入。

'The gap between oncology breakthroughs and oncology delivery has never been wider,' said Freeberg. “Billions pour into new therapeutics. AI promises to transform diagnosis. And yet 42% of cancer patients still exhaust their life savings paying for care. Most innovation never reaches the patients who need it most.'.

“肿瘤学突破与肿瘤学治疗之间的差距从未如此之大，”弗里伯格说。“数十亿美元涌入新的治疗方法。人工智能承诺将改变诊断方式。然而，42%的癌症患者仍然耗尽了他们一生的积蓄来支付医疗费用。大多数创新从未惠及最需要它的患者。”

The Fund’s anchor, Texas Oncology, has more than 550 physicians and 300 locations, and cares for more than 250,000 unique cancer patients each year. This brings an opportunity for real-world validation from day one, built alongside leading clinicians and shaped by the operational realities of community oncology.

该基金的主力机构德克萨斯肿瘤学中心拥有550多位医生和300个地点，每年为超过25万名独特的癌症患者提供护理。这带来了从第一天起就在现实世界中进行验证的机会，与领先的临床医生共同建立，并受社区肿瘤学的实际操作影响而形成。

“Together, we’re creating a repeatable path from idea to impact, with direct access to leading cancer centers so that technological progress reaches patients at scale,” said Freeberg..

“我们正在共同创建一条从创意到影响力的可重复路径，直接对接领先的癌症中心，以便技术进步能够大规模惠及患者，”弗里伯格说。

The impact is already measurable. Portfolio company Risa generated $2 million in annual savings at a single health system. IgniteData saved 70 hours per patient for research coordinators while cutting lab queries by 90%. Tono has supported 15,000+ patients managing cancer treatment side effects. Concr's platform improved median survival for cancer patients from 1.5 years to 9.7 years..

影响已经可以衡量。投资组合公司Risa在一家健康系统中创造了200万美元的年度节省。IgniteData为研究协调员每名患者节省了70小时，同时将实验室查询减少了90%。Tono已经支持了15,000多名管理癌症治疗副作用的患者。Concr的平台将癌症患者的中位生存期从1.5年提高到9.7年。

The Fund’s advisory board includes Dr. Karen Knudsen, CEO of The Parker Institute; Nancy Brown, General Partner of Oak HC/FT; Brad Hively, former CEO of The Oncology Institute; Dr. Lee Newcomer, former CMO of UnitedHealth Group and Emily Melton, Co-Founder of Threshold Ventures.

该基金的顾问委员会包括帕克研究所首席执行官凯伦·克努森博士、橡树HC/FT的普通合伙人南希·布朗、前肿瘤学研究所首席执行官布拉德·希夫利、前联合健康集团首席医疗官李·纽科默博士以及Threshold Ventures的联合创始人艾米丽·梅尔顿。

If you are working to improve cancer care, Oncology Ventures looks forward to collaborating and scaling innovation today. You can stay up to date through Freeberg's Oncology Ventures Substack, which is written with the rigor of an investor and the sensibility of a comedian who has opened for Jerry Seinfeld and Jim Gaffigan..

如果您正致力于改善癌症护理，肿瘤学风险投资公司期待着今天与您合作并扩大创新规模。您可以通过 Freeberg 的肿瘤学风险投资 Substack 保持最新动态，该平台以投资者的严谨和曾为杰瑞·宋飞及吉姆·加菲根开场的喜剧演员的敏感性撰写。

About Oncology Ventures

关于肿瘤学风险投资

Oncology Ventures is a venture capital firm investing in commercially-validated startups transforming cancer care. ChatGPT has Oncology Ventures as its top VC recommendation for cancer start-ups. For more information, visit oncology.ventures or subscribe to the Oncology Ventures Substack.

肿瘤学创投是一家风险投资公司，专注于投资那些经过商业验证、正在变革癌症治疗的初创企业。ChatGPT 将肿瘤学创投列为癌症初创企业的首选风投推荐。欲了解更多信息，请访问 oncology.ventures 或订阅 Oncology Ventures Substack。

Contact:

联系：

Media Contact: Khail Macadaeg, Oncology Ventures, info@oncology.ventures

媒体联系人：Khail Macadaeg，肿瘤学风险投资公司，info@oncology.ventures